National Cancer Act of 1971

• Provided broad authority for the National Cancer Program

• Granted the NCI Director “bypass budget” authority

• Mandated the presidentially appointed National Cancer Advisory Board and the President’s Cancer Panel
Frederick National Laboratory for Cancer Research
The SEER Program

Surveillance, Epidemiology and End Results

- Funded by NCI to support research on the diagnosis, treatment and outcomes of cancer since 1973
- 16 population-based registries covering 28% of the US population
  - Registries collect information on all cancer cases for residents of the state or region
  - Representing racial and ethnic minorities
  - Various geographic subgroups
- 450,000+ incident cases annually
Promoting Value, Affordability, and Innovation in Cancer Drug Treatment

A Report to the President of the United States from the President’s Cancer Panel
70 NCI Designated Cancer Centers
The New York Times

Good News for Women With Breast Cancer: Many Don’t Need Chemo

Many women with early-stage forms of the disease can forego chemo, based on a test that measures the activity of genes involved in breast cancer recurrence.

By DENISE GRADY JUNE 3, 2018

Vox

Thousands of women will avoid chemo thanks to a study funded by the breast cancer stamp

Many breast cancer patients don’t need chemo, a precision medicine study just found.

By Julia Belluz | @juliatronto | julia.belluz@voxmedia.com | Jun 5, 2018, 12:00pm EDT

Newsweek

What is Immunotherapy?: Woman with Terminal Breast CancerSaved by Pioneering Treatment

Researchers use immune-cell ‘army’ to battle another tough cancer

By KASHMIRA GANDER ON 6/5/18 AT 7:03 AM

CNBC

When it’s appropriate to use the C-word: A conversation with the director of the National Cancer Institute

Published 10:26 AM ET Mon, 4 June 2018 | Updated 12:21 PM ET Mon, 4 June 2018
Cancer Immunotherapy

PET scans of a patient with multiple myeloma treated with BCMA-targeted CAR T cells. Courtesy of J. Kochenderfer, NCI.
Targeting the KRAS$^{G12D}$ Neoantigen to Treat Cancer

L: Steven Rosenberg, MD. (NCI) R: Tran et al, NEJM 2016
Cancer Moonshot

Sept. 2016
- Blue Ribbon Panel Recommendations

- 21st Century Cures Act Authorized Funding for Cancer Moonshot

Apr.-Jun. 2017
- NCI Teams, Leaders & BSA Develop & Review Scientific Proposals Aligned with BRP Recommendations

Fall 2017
- $300M Awarded FY2018 FOAs Released
Cancer Moonshot FOAs

• Close to 50 Funding Opportunity Announcements to date and more to come

• 6 intramural initiatives

• Requirements related to data sharing and health disparities/underserved populations
### Partnership for Accelerating Cancer Therapies (PACT)

National Cancer Institute - Division of Cancer Treatment & Diagnosis

<table>
<thead>
<tr>
<th>Cancer Immune Monitoring Analysis Centers (CIMACs)</th>
<th>Dana-Farber</th>
<th>Stanford</th>
<th>Mount Sinai</th>
<th>MD Anderson</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cancer Immunologic Data Commons (CIDC)</td>
<td>Dana-Farber Cancer Institute</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Pharma Companies</th>
</tr>
</thead>
<tbody>
<tr>
<td>AbbVie</td>
</tr>
<tr>
<td>Amgen</td>
</tr>
<tr>
<td>Boehringer Ingelheim</td>
</tr>
<tr>
<td>BMS</td>
</tr>
<tr>
<td>Celgene</td>
</tr>
<tr>
<td>Genentech</td>
</tr>
<tr>
<td>Gilead</td>
</tr>
<tr>
<td>GSK</td>
</tr>
<tr>
<td>Janssen</td>
</tr>
<tr>
<td>Novartis</td>
</tr>
<tr>
<td>Pfizer</td>
</tr>
<tr>
<td>Sanofi</td>
</tr>
</tbody>
</table>
Key Focus Areas

**Basic Science**
Reaffirm our commitment to basic science to drive novel approaches and technologies

**Workforce Development**
Support the cancer research enterprise by focusing on the workforce of cancer investigators

**Big Data**
Increase data aggregation and interpretation to speed our work across the cancer enterprise

**Clinical Trials**
Fully realize the power of clinical trials through innovative design, administration, and analyses
Key Focus Areas

**BASIC SCIENCE**
Reaffirm our commitment to basic science to drive novel approaches and technologies

**WORKFORCE DEVELOPMENT**
Support the cancer research enterprise by focusing on the workforce of cancer investigators

**BIG DATA**
Increase data aggregation and interpretation to speed our work across the cancer enterprise

**CLINICAL TRIALS**
Fully realize the power of clinical trials through innovative design, administration, and analyses
Key Focus Areas

**Basic Science**
Reaffirm our commitment to basic science to drive novel approaches and technologies

**Workforce Development**
Support the cancer research enterprise by focusing on the workforce of cancer investigators

**Big Data**
Increase data aggregation and interpretation to speed our work across the cancer enterprise

**Clinical Trials**
Fully realize the power of clinical trials through innovative design, administration, and analyses
Key Focus Areas

**BASIC SCIENCE**
Reaffirm our commitment to basic science to drive novel approaches and technologies

**WORKFORCE DEVELOPMENT**
Support the cancer research enterprise by focusing on the workforce of cancer investigators

**BIG DATA**
Increase data aggregation and interpretation to speed our work across the cancer enterprise

**CLINICAL TRIALS**
Fully realize the power of clinical trials through innovative design, administration, and analyses
Key Focus Areas

**BASIC SCIENCE**
Reaffirm our commitment to basic science to drive novel approaches and technologies

**WORKFORCE DEVELOPMENT**
Support the cancer research enterprise by focusing on the workforce of cancer investigators

**BIG DATA**
Increase data aggregation and interpretation to speed our work across the cancer enterprise

**CLINICAL TRIALS**
Fully realize the power of clinical trials through innovative design, administration, and analyses
NCI Molecular Analysis for Therapy Choice (NCI-MATCH)

- Precision oncology trial to explore treating patients based on the molecular profiles of their tumors
- **1,118** sites in U.S. across NCTN and NCORP
## NCI Molecular Analysis for Therapy Choice (NCI-MATCH)

<table>
<thead>
<tr>
<th>Time period</th>
<th># enrolled</th>
<th># first samples submitted</th>
<th># first sample fail</th>
<th># assay complete</th>
<th># assigned to Rx</th>
<th># enrolled on Rx</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Pre Pause</td>
<td>794</td>
<td>739</td>
<td>116</td>
<td>645</td>
<td>54</td>
<td>27</td>
</tr>
<tr>
<td>Total Post Pause</td>
<td>5,603</td>
<td>5,223</td>
<td>425</td>
<td>4,912</td>
<td>937</td>
<td>660</td>
</tr>
<tr>
<td>Overall Total Screening Cohort</td>
<td>6,396</td>
<td>5,962</td>
<td>544</td>
<td>5,560</td>
<td>992</td>
<td>689</td>
</tr>
<tr>
<td>Total Outside Assay</td>
<td>74</td>
<td>36</td>
<td>2</td>
<td>68</td>
<td>59</td>
<td>45</td>
</tr>
</tbody>
</table>
NCI National Clinical Trials Network (NCTN)
We’re calling on one million people to lead the way toward better health.

What is precision medicine?
Precision medicine is health care that is based on you as an individual. It takes into account factors like where you live, what you do, and your family health history. The goal is to be able to tell people the best ways to stay healthy. If someone does get sick, precision medicine may help health care teams find the treatment that will work best.

How long will All of Us last?
All of Us may last for at least 10 years. We hope you will stay involved over time. If you join, you can withdraw ("quit") at any time for any reason without penalty.

Why should I join All of Us?
You will be contributing to research that may improve health for everyone. Here are some examples of what
Selected Collaborations with Other ICs

- New-Onset Diabetes and Pancreatic Cancer Cohort Study – with NIDDK
- Head and Neck Cancer Specialized Programs of Research Excellence (SPOREs) – with NIDCR
- Pediatric HIV/AIDS Cohort Study (PHACS) – with NICHD
- Improving Outcomes in Cancer Treatment-Related Cardiotoxicity – with NHLBI
- Center for Advanced Tissue Imaging (CAT-I) – with NIAID
- Immuno-Oncology Translation Network (IOTN):
  - Immunoprevention Research Projects - with NIEHS, NINDS, and NIDCR
  - Immunotherapy Research Projects - with NIEHS, NINDS, NIDCR, and NIAAA
- Gabriella Miller Kids First (Common Fund)
- NCI-NIMHD Collaborative Working Group on Chronic Liver Diseases and Liver Cancer